Treatment approach for fungal infections in critically ill patients admitted to intensive care units:: Results of a multicenter survey

被引:4
作者
Alvarez-Lerma, F
Nolla, J
Palomar, M
León, MA
机构
[1] Hosp Univ Mar, Serv Med Intens, Barcelona 08003, Spain
[2] Hosp Gen Valle Hebron, Barcelona, Spain
[3] Hosp Gen Cataluna, Barcelona, Spain
来源
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2003年 / 21卷 / 02期
关键词
candidemia; candiduria; multifocal candidiasis; Candida peritonitis; antifungal agents;
D O I
10.1157/13042864
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
INTRODUCTION. Two consensus conferences taking place in the United States and Spain were organized to optimize diagnosis and treatment of Candida spp. infections. Among other results, clinical scenarios in which early prescription of antifungal agents is indicated were identified. OBJECTIVE. To determine the criteria followed by physicians for prescribing antifungal agents in critically ill patients in our country and to investigate adherence to the guidelines proposed by the consensus conferences. METHODS. A questionnaire was designed and directed to 4(th)- and 5(th)-year residents in intensive care medicine and to specialists in intensive care with training in infectious diseases or other medical areas. Four case reports for which expert consensus indicates early antifungal treatment were included in the questionnaire; 1) recurrent peritonitis secondary to perforation of the digestive tract, with mixed flora including fungi; 2) persistent febrile syndrome in a patient with multiple mucosal fungal colonizations treated with broad-spectrum antibiotics; 3) candiduria and pyuria in a febrile patient; and 4) candidemia. RESULTS. A total of 135 questionnaires from 45 different ICUs were returned (60% response rate). In the candidemia and fungal peritonitis examples, early treatment with antifungal agents was indicated in 100% and 85.9% of responses, respectively, whereas for sepsis with multifocal candidiasis and candiduria associated with pyuria and fever, early treatment was prescribed in only 41.5% and 55.6% of responses, respectively. There were no significant differences in response with regard to degree of training of the physicians surveyed. Fluconazole prescription predominated, mainly at doses of 400 mg/day, in mixed peritonitis, disseminated candidiasis and candiduria, whereas amphotericin B lipid formulations were preferentially indicated in cases of candidemia. Antifungal treatment (early or late) was prescribed in all responses for candidemia, in 95.5% for mixed peritonitis (fungi and bacteria), in 79.5% for multifocal candidiasis in patients with persistent sepsis, and in 77.9% for candiduria with fever and pyuria. CONCLUSIONS. Adherence to recommendations from the consensus conferences was high among intensive medicine specialists, with no differences according to level of training in infectious diseases.
引用
收藏
页码:83 / 88
页数:6
相关论文
共 20 条
[1]
A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients [J].
AbeleHorn, M ;
Kopp, A ;
Sternberg, U ;
Ohly, A ;
Dauber, A ;
Russwurm, W ;
Buchinger, W ;
Nagengast, O ;
Emmerling, P .
INFECTION, 1996, 24 (06) :426-432
[2]
Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature [J].
Anaissie, EJ ;
Darouiche, RO ;
AbiSaid, D ;
Uzun, O ;
Mera, J ;
Gentry, LO ;
Williams, T ;
Kontoyiannis, DP ;
Karl, CL ;
Bodey, GP .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (05) :964-972
[3]
*C CONS SOC ESP ME, 1999, MED INTENSIVA, V23, P3
[4]
CALANDRA T, 1989, LANCET, V2, P1437, DOI 10.1016/S0140-6736(89)92043-6
[5]
High-dose therapy with fluconazole ≥800 mg day-1 [J].
Duswald, KH ;
Penk, A ;
Pittrow, L .
MYCOSES, 1997, 40 (7-8) :267-277
[6]
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [J].
Edwards, JE ;
Bodey, GP ;
Bowden, RA ;
Buchner, T ;
dePauw, BE ;
Filler, SG ;
Ghannoum, MA ;
Glauser, M ;
Herbrecht, R ;
Kauffman, CA ;
Kohno, S ;
Martino, P ;
Meunier, F ;
Mori, T ;
Pfaller, MA ;
Rex, JH ;
Rogers, TR ;
Rubin, RH ;
Solomkin, J ;
Viscoli, C ;
Walsh, TJ ;
White, M .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) :43-59
[7]
CANDIDEMIA IN A TERTIARY CARE HOSPITAL - EPIDEMIOLOGY, RISK-FACTORS, AND PREDICTORS OF MORTALITY [J].
FRASER, VJ ;
JONES, M ;
DUNKEL, J ;
STORFER, S ;
MEDOFF, G ;
DUNAGAN, WC .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (03) :414-421
[8]
JORDA R, 1999, INTENSIVE CARE ME S1, V25, P171
[9]
JUJATH P, 1993, INFECTION, V21, P377
[10]
LERMA FA, 2000, INTENSIVE CARE ME S1, V26, pS234